toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
Details
   print
  Record Links
Author Buchvald, F.; Bisgaard, H. url  doi
openurl 
  Title Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide Type Journal Article
  Year (down) 2003 Publication Annals of Allergy, Asthma & Immunology Abbreviated Journal Ann Allergy Asthma Immunol  
  Volume 91 Issue 3 Pages 309-313  
  Keywords Acetates/*therapeutic use; Administration, Inhalation; Adolescent; Albuterol/*analogs & derivatives/*therapeutic use; Asthma/*drug therapy/metabolism; Breath Tests; Bronchodilator Agents/*therapeutic use; Budesonide/therapeutic use; Child; Cross-Over Studies; Double-Blind Method; Humans; Nitric Oxide/analysis/metabolism; Quinolines/*therapeutic use; Salmeterol Xinafoate  
  Abstract BACKGROUND: Inhaled, long-acting beta2-agonists or antileukotrienes are alternatives as add-on therapy for asthmatic children taking regular inhaled steroids. Any complementary effects would be relevant to the choice between these alternatives. Exhaled nitric oxide (FeNO) may reflect these effects. OBJECTIVE: To compare the control of FeNO provided by salmeterol or montelukast add-on therapy in asthmatic children undergoing regular maintenance treatment with a daily dose of 400 microg of budesonide. METHODS: The study included children with increased FeNO despite regular treatment with budesonide, 400 microg/d, and normal lung function. Montelukast, 5 mg/d, salmeterol, 50 microg twice daily, or placebo was compared as add-on therapy to budesonide, 400 microg, in a randomized, double-blind, double-dummy, crossover study. RESULTS: Twenty-two children completed the trial. The geometric mean FeNO level was 20 ppb (95% confidence interval [CI], 15-27 ppb) after salmeterol, which was significantly higher than after montelukast (mean, 15 ppb; 95% CI, 11-18 ppb; P = 0.002) and placebo (mean, 15 ppb; 95% CI, 10-21 ppb; P = 0.03). There was no difference in FeNO between the montelukast and placebo groups. Mean forced expiratory volume in 1 second (FEV1) was significantly increased after salmeterol (mean, 2.63 L; 95% CI, 2.34-2.91 L) compared with placebo (mean, 2.48 L; 95% CI, 2.19-2.77 L). Montelukast (mean, 2.57 L; 95% CI, 2.33-2.80 L) was no different than placebo. CONCLUSIONS: The FeNO levels were significantly higher after salmeterol add-on treatment compared with both placebo and montelukast add-on treatment. Salmeterol significantly improved lung function (FEV1) compared with placebo and nonsignificantly compared with montelukast. Montelukast failed to reduce FeNO and improve lung function compared with placebo in this group of children taking regular budesonide, 400 microg.  
  Address Department of Pediatrics, Rigshospitalet, National University Hospital, Copenhagen, Denmark  
  Corporate Author Thesis  
  Impact Factor 02,599 First Author Buchvald, F. Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Senior Author Bisgaard, H.  
  ISSN 1081-1206 ISBN Medium  
  Area Expedition Conference  
  Notes PMID:14533665 Approved no  
  Call Number Serial 164  
Permanent link to this record
Select All    Deselect All
 |   | 
Details
   print

Save Citations:
Export Records: